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Abstract
Background & Aims: Inflammation is a major risk factor for development of colorectal cancer (CRC). Prostaglandin synthase
cyclooxygenase-2 (COX-2) encoded by the PTGS2 gene is the rate limiting enzyme in prostaglandin synthesis and therefore
plays a distinct role as regulator of inflammation.
Methods: PTGS2 mRNA levels were determined in intestinal tissues from 85 intestinal adenoma cases, 115 CRC cases, and 17
healthy controls. The functional PTGS2 polymorphisms A-1195G (rs689466), G-765C (rs20417), T8473C (rs5275) were
assessed in 200 CRC cases, 991 adenoma cases and 399 controls from the Norwegian KAM cohort.
Results: PTGS2 mRNA levels were higher in mild/moderate adenoma tissue compared to morphologically normal tissue
from the same individual (P,0.0001) and (P,0.035) and compared to mucosa from healthy individuals (P,0.0039) and (P,
0.0027), respectively. In CRC patients, PTGS2 mRNA levels were 8–9 times higher both in morphologically normal tissue and
in cancer tissue, compared to healthy individuals (P,0.0001). PTGS2 A-1195G variant allele carriers were at reduced risk of
CRC (odds ratio (OR) = 0.52, 95% confidence interval (95% CI): 0.28–0.99, P = 0.047). Homozygous carriers of the haplotype
encompassing the A-1195G and G-765C wild type alleles and the T8473C variant allele (PTGS2 AGC) were at increased risk of
CRC as compared to homozygous carriers of the PTGS2 AGT (A-1195G, G-765C, T8473C) haplotype (OR = 5.37, 95% CI: 1.40–
20.5, P = 0.014). No association between the investigated polymorphisms and PTGS2 mRNA levels could be detected.
Conclusion: High intestinal PTGS2 mRNA level is an early event in colorectal cancer development as it occurs already in
mild/moderate dysplasia. PTGS2 polymorphisms that have been associated with altered PTGS2 mRNA levels/COX-2 activity
in some studies, although not the present study, were associated with colorectal cancer risk. Thus, both PTGS2
polymorphisms and PTGS2 mRNA levels may provide information regarding CRC risk.
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Introduction
Colorectal cancer (CRC) constitutes the second most common
cancer and the second most common cause of cancer-related
deaths [1]. In the Western World, one in 20 will develop CRC
before the age of 75 years [2]. Furthermore, the prevalence is
increasing worldwide due to demographic trends and adaption to
westernized lifestyle in developing countries [1]. Thus, identifica-
tion of underlying biological mechanisms is of high importance in
order to develop new preventive and treatment strategies.
Multiple environmental and genetic factors are involved in
CRC [2], and intestinal inflammation has been found to be a
major risk factor [3–6]. Cycloxygenase enzymes COX-1 and
COX-2 encoded by the PTGS1 and PTGS2 genes catalyse the
rate limiting step in the prostaglandin synthesis, which is a key
regulator of inflammation. The PTGS1 gene is constitutively
expressed in many cell types, whereas the expression of the
PTGS2 gene is controlled by pro-inflammatory and mitogenic
stimuli. Several polymorphisms in PTGS2 that influence COX-2
enzyme levels have been described. The variant G-allele of
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PTGS2 A-1195G destroys a c-Myb binding site in the promoter
region resulting in lowered PTGS2 mRNA levels in oesophageal
tissue [7]. The PTGS2 G-765 C polymorphism is located in a
Stimulatory protein 1 (SP1) binding site. The G-765C C-allele had
significantly 30% lower promoter activity compared with the G-
allele in lung tissue [8]. In accordance with this higher COX-2
levels were found in the normal duodenal mucosa of patients with
familial adenomatous polyposis who were homozygous carriers of
the G-allele, compared to carriers of the C-allele [9]. On the other
hand, no statistically significant differences between -765C and -
765G were observed in transient reporter gene transfection studies
in HeLa cells and no statistically significant difference was found in
oesophageal tissue [7]. The PTGS2 T8473C SNP is located in the
39untranslated region of the PTGS2 mRNA. Through binding at
the 8473 39UTR site, Mir-542-3p targets PTGS2 mRNA for
decay. The variant C-allele at 8473 disrupts miRNA-mRNA
interaction leading to increased half-life of the PTGS2 mRNA
[10]. Carriers of the variant alleles of these SNPs thus have a
genetically determined altered level of PTGS2 mRNA in tissues
where the transcription factor or miRNA in question are expressed
and functional.
High COX-2 levels have been found in a large proportion of
adenoma and carcinoma tissues by immunohistochemistry
[11,12]. It is, however, not clear whether increased COX-2
expression occurs early in the adenoma-carcinoma sequence,
thereby promoting carcinogenesis or whether it occurs late,
possibly as a consequence of the carcinogenesis. In this study we
assessed the levels of PTGS2 mRNA in intestinal tissue from
healthy subjects and adenoma and carcinoma cases using the
Norwegian KAM cohort [13–24]. Tissue from the cases ranged
from morphologically normal intestinal tissue to adenomas and
carcinomas. We also assessed the potential risk of CRC associated
with functional PTGS2 gene polymorphisms. Furthermore, we
assessed the association between the genetic variants in PTGS2
and PTGS2 mRNA levels.
Materials and Methods
Study cohort
The KAM (Kolorektal cancer, Arv og Miljø) cohort is based on
the screening group of the Norwegian Colorectal Cancer
Prevention study (the NORCCAP study) in the county of
Telemark and a series of clinical CRC cases operated at Telemark
Hospital (Skien) and Ullevaal University Hospital (Oslo) [15,25].
In short, 20,780 healthy men and women, age 50–64 years of age,
drawn at random from the population registry in Oslo (urban) and
the county of Telemark (mixed urban and rural) were invited to
have a flexible sigmoidoscopy screening examination.
The KAM biobank consists of samples from individuals with
adenomas in the large intestine (991 adenomas and 53 hyperplas-
tic polyps), 234 cases with adenocarcinomas and 400 controls,
defined as individuals with normal findings at flexible sigmoidos-
copy screening. The study was performed in accordance with the
Helsinki Declaration. The Regional Ethics Committee and the
Data Inspectorate approved the KAM study (S-98190, 2009/
2021). The ID number for the study is NCT00119912 at
ClinicalTrials.gov [26]. Written and verbal consent was obtained
from all participants.
Biological Material
Blood samples were available from 200 cases with CRC, 991
cases with adenomas and 399 controls and intestinal tissue was
available from 115 cases with adenocarcinoma, 85 cases with
adenomas and 17 healthy individuals [14–24]. From individuals
with adenomas, control tissue was sampled 30 cm above the anus.
From patients with carcinomas, two control samples were taken
from the surgically specimen. One sample was taken adjacent to
the cancer (normal adjacent) and the other sample was taken as
distant from the cancer as possible (normal distant). Matching
samples were available from 74 cases with mild-moderate
dysplasia, 9 cases with severe dysplasia, and 93 (distant normal
tissue samples) and 103 (adjacent tissue samples) CRC cases,
respectively. The histology of the adenomas was examined
independently by two pathologists, who categorised the degree
of dysplasia as either mild/moderate (n = 76) or severe (n = 9).
Consensus was reached in all cases. In a few cases biopsies of
material suspected to be dysplastic were after examination of the
histology categorized as normal and were classified as biopsies
from healthy individuals (n = 17). Carcinomas were classified
according to Dukes staging. Characteristics of the study population
are shown in Table 1.
Real-time reverse transcriptase polymerase chain
reaction
The tissue samples were frozen as soon as possible after surgery
and stored in liquid nitrogen until RNA purification. Total RNA
and cDNA synthesis was purified from tissue as described [19].
Quantitative real time RT-PCR of PTGS2 was performed on the
ABI7300 sequence detection system (Applied Biosystems) in
Universal PCRMaster Mix (part.no 4326614, Applied Biosystems)
using 125 nM probe and 600 nM primers. Primers and probe
were: COX-2 forward 59-ATT GTA CCC GGA CAG GAT TCT
ATG -39; COX-2 reverse 59-TTT GGA GTG GGT TTC AGA
AAT AAT T-39; COX-2 probe 59- FAM-CTG CTC AAC ACC
GGA ATT TTT GAC AAG AAT-BHQ-39.
Primers were designed within different exons and with the
probe covering an exon-exon border to prevent amplification of
genomic DNA. Primers and probes were obtained from TAG
Copenhagen (Denmark). The endogenous b-actin control was
obtained pre-developed (part.no.4310881E) from Applied Biosys-
tems. In a validation experiment using a control sample, a dilution
series was assayed by the comparative Ct method [27]. The assays
were quantitative over a range of 128-fold dilution. Samples were
quantified in triplicates. The CV of triplicates was 0.06 or less. The
CV of repeated measurements of the same sample (the control) in
separate experiments was 0.25, indicating the day-to-day variation
of the assay. Negative controls (where the RNA was not converted
into cDNA) and positive controls were included in all runs.
Samples for which either the b-actin or PTGS2 values fell outside
the upper or lower limits of the standard curve were excluded from
the study.
Genotyping
Genomic DNA was isolated from blood samples according to
standard procedures with minor modifications as described
previously [28]. All analyses were run blinded to the case-control
status. PTGS2 T8473C (rs5275) was genotyped using the
following primers PTGS2 FP 59-GCA TCT TCC ATG ATG
CAT TAG AAG TAA C-39; PTGS2 RP 59-GGT AAT GTC
TAA TTT AAA TAT TCA TTT AAT AAT GCA CTG ATA
CC-39; Probe for T allele 59-FAM-ACT TTT GGT TAT TTT
TC-MGB-39; Probe for C allele 59-VIC-CTT TTG GTC ATT
TTT C-MGB3’. Controls were included in each run and repeated
genotyping of a random 10% subset yielded 100% identical
genotypes. PTGS2 G-765C (rs20417) and PTGS2 A-1195G
(rs689466) were genotyped by KBioscience (kbioscience.co.uk).
Genotype distributions of the polymorphisms among the controls
PTGS2 Polymorphisms and Intestinal mRNA Levels
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did not deviate from Hardy-Weinberg equilibrium. Haplotypes
were inferred manually.
Statistics
Minitab 16 was used for the statistical analysis of the association
between genotypes and risk of adenomas and risk of colorectal
cancer adjusted for age and gender. All statistical analyses of
mRNA levels were performed using SAS (release 9.3, SAS
Institute, Cary, NC). Linear regression (PROC GLM) was used
to compare mRNA levels in tissue from healthy participants versus
tissues from affected participants with adjustment for age and
gender. A paired t-test (PROC TTEST) was used to compare
mRNA levels from control tissue and affected tissue from the same
individual. All values of mRNA expression levels were log-
transformed to correct for left-skewed distribution.
Results
PTGS2 mRNA levels in intestinal tissue
PTGS2 mRNA levels were increased in both mild/moderate
and severe dysplastic tissue and in morphologically normal and
affected tissue from cancer patients. PTGS2 mRNA levels were
significantly higher in mild/moderate dysplasia (P,0.0039), in
severe dysplasia (P,0.0027), in morphologically normal mucosa
from cancer patient, in both distant and adjacent to the tumour
(P,0.0001 for both) and in tumour tissues (P,0.0001) as
compared to the mucosa from healthy individuals (Figure 1 and
Table 2). PTGS2 mRNA levels were on an average almost 9 fold
higher in cancerous tissue compared to tissue from healthy
individuals. When comparing normal and affected tissue from the
same individual, a statistically significant difference was seen in
individuals with mild/moderate dysplasia (P,0.0001) and severe
dysplasia (P,0.035) (Table 2). There was an inverse correlation
between age and PTGS2 mRNA levels (Figure S1). No correlation
between the PTGS2 mRNA levels and gender or Duke’s stage of
the carcinoma (Dukes stage A (n = 19), stage B (n= 47), and stage
C (n= 29)) was found (data not shown).
Associations between PTGS2 polymorphisms and CRC
Carriers of the PTGS2 A-1195G variant G-allele were at lower
risk of CRC (OR=0.52, 95% CI: 0.28–0.99, P = 0.047) (Table 3).
Furthermore, in a haplotype analysis, homozygous carriers of the
haplotype encompassing the PTGS2 T8473C variant allele (AGC)
were at increased risk of CRC (OR=5.37, 95% CI: 1.40–20.5,
P= 0.014) compared to homozygous carriers of the reference
PTGS2 AGT (A-1195G, G-765C, T8473C) haplotype (Table 4).
PTGS2 gene polymorphisms and PTGS2 mRNA levels
PTGS2 mRNA levels in intestinal adenoma cases (left panel)
and carcinoma cases (right panel) were subdivided by PTGS2 A-
1195G (rs689466), PTGS2 G-765C (rs20417), and PTGS2
T8473C (rs5275) genotypes, respectively (Figure 2). No statistically
significant associations between genotypes and PTGS2 mRNA
levels were found (Figure 2).
Discussion
The role of COX-2 in colorectal cancer carcinogenesis is not
clear. We have therefore determined the PTGS2 mRNA levels
during colorectal cancer carcinogenesis and found that the mRNA
level of PTGS2 is increased already in mild/moderate dysplasia
and in severe dysplasia as compared to morphologically normal
tissue from the same individual and as compared to normal
mucosa from healthy individuals. Furthermore, the PTGS2
mRNA levels were increased both in normal and affected tissue
from colorectal cancer patients compared to tissue from healthy
control individuals. This is in accordance with previous investiga-
tions where COX-2 enzyme was detected in colorectal adenoma
and carcinoma tissue by immunohistochemistry but was absent
from normal tissue from healthy individuals and normal tissue
from individuals with dysplasia [11,12]. This indicates that high
COX-2 expression occurs as an early event in colorectal cancer
carcinogenesis.
The role of PTGS2 in colorectal carcinogenesis was also studied
by assessing the association of three functional polymorphisms in
PTGS2 with risk of development of adenoma and CRC. The
PTGS2 A-1195G variant G-allele and the PTGS2 G-765C
variant C-allele lead to lower transcription of the PTSG2 gene.
Table 1. Study participant description.
Genotyping study
Controls Adenomas Carcinomas
No. of subjects (N) 399 991 200
Male (N (%)) 157 (39.3) 607 (61.2) 110 (55.0)
Female (N (%)) 242 (60.7) 384 (38.8) 90 (45.0)
Age Mean (SD) 54.2 (3.3) 57.2 (3.7) 67.4 (11.2)
mRNA study
Controls Adenomas Carcinomas
Mild/moderate Severe
No. of subjects (N) 17 76 9 115
Male (N (%)) 5 (31) 52 (68) 4 (44) 64 (56)
Female (N (%)) 11 (69) 24 (32) 5 (56) 51 (44)
Age Mean (SD) 57.2 (4.7) 56.8 (3.8) 55.4 (2.9) 69.8 (11.4)
doi:10.1371/journal.pone.0105254.t001
PTGS2 Polymorphisms and Intestinal mRNA Levels
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Conversely, the PTGS2 T8473C variant C-allele leads to higher
mRNA levels due to impaired mRNA degradation. The PTGS2
A-1195G variant G-allele co-segregates with the wild-type alleles
of the two other polymorphisms, whereas the PTGS2 G-765C
variant C- allele and T8473C variant C-allele are in tight linkage
[29]. The allele frequency of the T8473C variant C- allele is much
higher than the allele frequency of the G-765C variant C-allele
[30,31].
Figure 1. PTGS2 mRNA expression during colorectal carcinogenesis. Normalised PTGS2 mRNA levels in healthy individuals, individuals with
mild/moderate dysplasia, severe dysplasia, and individuals with carcinomas as determined by real-time RT-PCR. Samples from healthy individuals
(cross), normal and affected tissue from individuals with mild/moderate dysplasia (square), normal and affected tissue from individuals with severe
dysplasia (triangle), and normal adjacent, normal distant and cancerous tissue from colorectal cancer patients (circle) were analyzed for PTGS2 mRNA
levels relative to the b-actin mRNA levels. The horizontal line represents the mean values. The p-value indicated with a ¤ was calculated using linear
regression to compare mRNA levels in tissue from healthy participants versus tissues from affected participants with adjustment for age and gender.
doi:10.1371/journal.pone.0105254.g001
Table 2. PTGS2 mRNA levels in morphologically normal and affected tissues normalised to the b-actin mRNA level.
Normal Tissue Adenoma/Carcinoma Tissue
Mean ± S.D. Pa Mean ± S.D. Pa Pb
Healthy individuals 0.0007260.00061
Individuals with mild/moderate dysplasia 0.0008360.00074 0.17 0.001860.0018 0.0039 ,0.0001
Individuals with severe dysplasia 0.0009660.00070 0.32 0.01160.026 0.0027 0.035
Cancer patients 0.006860.0097 (distant) ,0.0001 0.98
0.007160.011 ,0.0001
0.006160.0088 (adjacent) ,0.0001 0.64
aP values for comparison to healthy individuals adjusted for age and gender.
bP value for comparison to morphologically normal tissue from the same individual using Paired Student’s T-test.
doi:10.1371/journal.pone.0105254.t002
PTGS2 Polymorphisms and Intestinal mRNA Levels
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We found that PTGS2 A-1195G G- variant allele carriers were
at reduced risk of CRC. We were unable to find any association
between PTGS2 A-1195G genotype and PTGS2 mRNA levels,
although analysis of the normal and affected tissue from cancer
patients showed a tendency towards PTGS2 A-1195G variant G-
allele carriers having a lower mean level of PTGS2 mRNA
compared to individuals homozygous for the wild-type allele.
Due to the linkage of the SNPs most individuals carry a mixture
of SNPs predisposing for low PTGS2 mRNA level and SNPs
predisposing for high PTGS2 mRNA level. However, individuals
homozygous for the haplotype encompassing PTGS2 T8473C
variant allele (A-1195G, G-765C, T8473C) (AGC) only carry
alleles predisposing for high PTGS2 mRNA levels. Homozygous
carriers of the haplotype encompassing PTGS2 T8473C variant
allele (A-1195G, G-765C, T8473C) (AGC) were at 5-fold
increased risk of CRC (P= 0.014) compared to homozygous
carriers of the reference PTGS2 AGT haplotype. In the present
study we were unable to detect an altered risk of cancer for carriers
of the G-765C variant C-allele, probably due to the strong linkage
to T8473C variant C-allele, an allele with the opposite effects on
the PTGS2 mRNA level. Since the variant alleles of A-1195G and
T8473C are present on different haplotypes, the two results point
to the same conclusion, namely that high PTGS2 mRNA level is
associated with increased risk of CRC. Thus, results obtained in
the present study suggest that the genotypes at PTSG2 A-1195G
and T8473C affect the risk of cancer. However, we were unable to
demonstrate an altered PTGS2 mRNA level depending on the
genotype at position -1195 and 8473. Our finding correlate well
with a meta-analysis finding that homozygosity for the PTGS2-
1195 G-allele is associated with reduced risk of digestive system
cancers [32]. However, the validity of this meta-analysis is unclear
as we noted that for several of the papers analysed, the allele
frequencies of G- and A-alleles of PTGS2 A-1195G do not match
the allele frequencies in the original papers [33,34]. Our results are
also in accordance with another meta-analysis showing that there
is no evidence that the genotype at PTGS2-765 influences risk of
colorectal cancer except in populations of Asian descent [35].
However, the results obtained in the present study are in contrast
with results from the Danish prospective Diet, Cancer and Health
cohort, where we found that high PTGS2 mRNA level-associated
PTGS2 variant alleles were associated with lower risk of CRC
[36]. This may be explained by effect modification of associations
between the PTGS2 SNP and colorectal cancer risk by dietary
factors that may differ between Danish and Norwegian popula-
tions as for example fish and fruit and vegetables [36].
Our results suggest that high PTGS2 expression is an early
event in CRC carcinogenesis. Long term use of aspirin and other
NSAIDs including selective COX-2 inhibitors have been associ-
ated with lowered risk of CRC [37,38]. Also the present study and
previous meta-analyses suggest that the genotypes at PTGS2 A-
1195G and T8473C but not G-765C are associated with altered
risk of colorectal cancer, although we were unable to demonstrate
association to altered levels of PTGS2 mRNA levels for any of the
three SNPs. This may suggest that the polymorphisms influence
risk in other ways than by affecting PTGS2 transcription levels.
Conclusion
In conclusion, this study suggests that increased PTGS2 mRNA
level is an early event in colorectal cancer carcinogenesis. PTGS2
SNPs that have been associated with altered PTGS2 mRNA
levels/COX-2 activity in some studies, although not the present
study, were associated with colorectal cancer risk. Thus, bothT
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Figure 2. PTGS2 gene polymorphisms and PTGS2 mRNA level. Normalised PTGS2 mRNA levels in morphologically normal and affected
intestinal tissue from individuals with adenomas (left panel) and CRC (right panel) subdivided by PTGS2 A-1195G (rs689466), G-765C (rs20417),
T8473C (rs5275) genotypes. The number of individuals with each genotype is indicated in brackets above the column.
doi:10.1371/journal.pone.0105254.g002
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PTGS2 polymorphisms and PTGS2 mRNA levels may provide
information regarding CRC risk.
Supporting Information
Figure S1 Normalised PTGS2 mRNA levels decreased
with age in normal tissue from individuals with
dysplasia.
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